dornase alfa (Pulmozyme)

01/01/2001 - "Most respiratory complications in cystic fibrosis (CF) arise from abnormally viscid mucus, and rhDNase has shown to be effective in enhancing mucous clearance. "
08/01/1995 - "Treatment with either rhDNase or high-frequency oscillation has been shown to be effective in improving the physical and transport properties of airway secretions in cystic fibrosis (CF). "
04/01/1995 - "Administration of rhDNase improved the severity of dyspnoea, cystic fibrosis related symptoms, and the modified Taussig/NIH score (not statistically significant). "
04/01/1995 - "Administration of rhDNase was safe, well tolerated, and improved pulmonary function in patients with cystic fibrosis. "
06/01/1999 - "Patients with cystic fibrosis (CF) receiving dornase-alfa had improved pulmonary function relative to a control group in a large randomized phase III controlled study. "

01/01/2009 - "In subgroup 1a, 16 patients had complete resolution of atelectases and minimal change in dystelectases after a treatment of 24 hours rhDNase, compared with the control group of 17 patients, who had 7 atelectases and 10 dystelectases at baseline and an improvement in only 1 out of 17 (6 %) patients after 24h. "
12/01/2012 - "There was no significant improvement in the chest X-ray atelectasis score in mechanically ventilated patients with new onset atelectasis who were nebulized with Dornase alpha twice a day. "
05/01/2009 - "rhDNase was effective in significantly improving established atelectasis without any major changes in gas exchange and ventilatory parameters. "
10/01/2014 - "The use of dornase alpha can be effective for the management of pulmonary atelectasis that develops following congenital heart surgery."
08/01/2014 - "The majority of patients experienced improvement in atelectasis, suggesting benefit after receiving treatment with dornase alfa. "

03/01/1995 - "Short-term (10-day) Phase I and II clinical trials showed dornase alfa to be safe and effective in improving pulmonary function in clinically stable CF patients with mild to moderate pulmonary disease (FVC > or = 40% of predicted value). "
07/01/1997 - "These in vitro results suggest that combined treatment with rhDNase and HS should be evaluated further as a potential mucotropic approach to augment the clearance of purulent sputum in CF lung disease."
04/01/1996 - "This article reviews the in vivo clinical studies conducted to determine the safety and efficacy of rhDNase in the treatment of pulmonary disease in CF. "
01/01/2018 - "In the second trial, rhDNase led to a greater increase in FEV1 % predicted than hypertonic saline (5 mL twice daily) at 12 weeks in participants with moderate to severe lung disease, MD 8.00% (95% CI 2.00 to 14.00) (low-quality evidence). "
07/01/2015 - "Using existing data from three studies we assessed the sensitivity of moment ratios and abbreviated LCIs to (i) detect mild-to-moderate CF lung disease and (ii) detect treatment effects after 4 weeks of hypertonic saline or dornase alfa inhalation. "

08/01/1998 - "The aim of this study was to determine whether airway inflammation would decrease after administration of rhDNase. "
03/15/2004 - "We conclude that in patients with CF, an increase in neutrophilic airway inflammation is found that is positively influenced by rhDNase treatment."
08/01/2002 - "In summary, we were unable to show that rhDNase or HS promote airway inflammation in CF."
08/01/1998 - "Although the administration of rhDNase resulted in significant improvements in FEV1, there was no evidence of accompanying changes in airway inflammation."
03/01/2012 - "These encouraging results, possibly linked to indirect effects on inflammation, suggest a greater role for dornase alfa therapy in the early treatment of CF, where it may help preserve lung function and potentially extend survival."

04/01/1996 - "A significant improvement in mucus cough transport was also induced by rhDNase from 25.5 mm with placebo to 27.0 mm with either 2 or 4 micrograms.mL-1 rhDNase. "
05/01/2001 - "There was improvement in the parents' assessments of the patients' well-being, with improvement in physical activity, decreased cough, sleep quality, and appetite in those subjects receiving rhDNase. "
09/01/1997 - "Some quality-of-life (QOL) domains (mainly cough frequency and chest congestion) have shown modest improvement in patients treated with dornase alfa, mainly those with mild CF. "
01/01/1997 - "Thus the interaction of inhaled rhDNase with the purulent mucus and the endobronchial inflammatory processes may induce changes that result in rheological properties favoring clearance of sputum by cough."
02/01/1996 - "The calculated cough clearance index was also improved following treatment with rhDNase. "